Bristol Myers Squibb CEO says FDA stability is critical for drug innovation

Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade

Fireside Chat with Chris Boerner and Euan Ashley | Stanford Medicine's AI in Life Sciences Symposium

Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer

Siddhart Nahata & Christopher Boerner – Morgan Stanley Global Healthcare Conference 2025

Pharma exec won't commit to selling life-saving drug in U.S. for lower price offered in Canada

Bristol-Myers Squibb Company (NYSE: BMY) Rings The Closing Bell®